Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Lantero-Rodriguez

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Diabetologia|February 12, 2017
AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectinEmma Börgeson, Ville Wallenius, Gulam H Syed, et al.
Alzheimer'S Research & Therapy|May 18, 2024
Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderlyMikko Koivumäki, Laura Ekblad, Juan Lantero-Rodriguez, et al.
Acta Neuropathologica|February 23, 2022
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive changeDenis S Smirnov, Nicholas J Ashton, Kaj Blennow, et al.
Brain : a Journal of Neurology|March 21, 2022
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseasesAnniina Snellman, Juan Lantero-Rodriguez, Andreja Emeršič, et al.
Neurobiology of Disease|June 2, 2023
Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's diseaseAnniina Snellman, Laura L Ekblad, Nicholas J Ashton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2020
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosisThomas K Karikari, Andreja Emeršič, Agathe Vrillon, et al.
Nature Reviews. Neurology|May 18, 2022
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utilityThomas K Karikari, Nicholas J Ashton, Gunnar Brinkmalm, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
P-TAU205 IS A BIOMARKER LINKED TO TAU-PET ABNORMALITY: A CROSS-SECTIONAL AND LONGITUDINAL STUDYJuan Lantero-Rodriguez, Shorena Janelidze, Sebastian Palmqvist, et al.
JAMA Neurology|December 4, 2023
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid ImmunotherapiesNiklas Mattsson-Carlgren, Lyduine E Collij, Erik Stomrud, et al.
Journal of Alzheimer'S Disease : JAD|August 18, 2020
Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar DegenerationAlberto Benussi, Nicholas J Ashton, Thomas K Karikari, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Diabetologia|February 12, 2017
AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectinEmma Börgeson, Ville Wallenius, Gulam H Syed, et al.
Alzheimer'S Research & Therapy|May 18, 2024
Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderlyMikko Koivumäki, Laura Ekblad, Juan Lantero-Rodriguez, et al.
Acta Neuropathologica|February 23, 2022
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive changeDenis S Smirnov, Nicholas J Ashton, Kaj Blennow, et al.
Brain : a Journal of Neurology|March 21, 2022
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseasesAnniina Snellman, Juan Lantero-Rodriguez, Andreja Emeršič, et al.
Neurobiology of Disease|June 2, 2023
Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's diseaseAnniina Snellman, Laura L Ekblad, Nicholas J Ashton, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2020
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosisThomas K Karikari, Andreja Emeršič, Agathe Vrillon, et al.
Nature Reviews. Neurology|May 18, 2022
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utilityThomas K Karikari, Nicholas J Ashton, Gunnar Brinkmalm, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
P-TAU205 IS A BIOMARKER LINKED TO TAU-PET ABNORMALITY: A CROSS-SECTIONAL AND LONGITUDINAL STUDYJuan Lantero-Rodriguez, Shorena Janelidze, Sebastian Palmqvist, et al.
JAMA Neurology|December 4, 2023
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid ImmunotherapiesNiklas Mattsson-Carlgren, Lyduine E Collij, Erik Stomrud, et al.
Journal of Alzheimer'S Disease : JAD|August 18, 2020
Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar DegenerationAlberto Benussi, Nicholas J Ashton, Thomas K Karikari, et al.
Pageof 7